Work

PSMA‐PET – Prostate Cancer Imaging in the Modern Era

Year: 2025

Type: article

Abstract: ABSTRACT The management of prostate cancer relies on accurate staging. Prostate specific membrane antigen (PSMA) is a transmembrane glycoprotein highly expressed in prostate tissues, particularly prostate cancer. PSMA positron emission tomography (PSMA‐PET) is an emerging imaging modality that has recently established roles in prostate cancer imaging. In this narrative review, we aim to provide a concise overview of PSMA‐PET imaging including underlying principles, current roles in prostate cancer imaging and supporting evidence, and potential future directions. Conventional prostate cancer staging relied on a combination of CT and a whole body bone scan (WBBS). In existing studies, PSMA‐PET demonstrates superiority over conventional staging for prostate cancer in initial staging, as well as in re‐staging after biochemical recurrence. Currently, applications of PSMA and PSMA‐PET beyond prostate cancer imaging, such as in theranostics, and imaging of non‐prostatic diseases are being explored.

Source: Trends in Urology & Men s Health

DOI: 10.1002/tre.70001

Authors: Shravankrishna Ananthapadmanabhan, Zoe Williams, Jonathan Kam, Isaac Arpit Thangasamy

Institutions: Nepean Hospital, The University of Sydney

Language: English

Topic: Prostate Cancer Diagnosis and Treatment

Subfield: Urology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $2,000